Skip to main content

FDA Alerts

The FDA approved dupiliumab for the treatment of moderate to severe atopic dermatitis in adolescents.
The FDA has approved a new biosimilar for patients with various autoimmune diseases, including psoriasis and psoriatic arthritis.​​​​​​​
The FDA approved the first treatment specifically for patients with advanced cutaneous squamous cell carcinoma.
The FDA has approved a new topical, once-daily lotion for the treatment of acne vulgaris in patients aged 9 years and older.​​​​​​​
The FDA has approved a combination therapy to treat unresectable or metastatic melanoma with BRAF mutations.
The FDA has approved the inclusion of new evidence to the prescribing label for secukinumab for the treatment of psoriatic arthritis.
The FDA has approved expanding the indication for certolizumab pegol (Cimzia) to include adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The FDA has approved a new dermal filler for the correction of age-related volume loss in the back of the hand for adult patients.
The US Food and Drug Administration has approved a combination therapy for patients with melanoma with BRAF V600E or V600K melanoma mutations. For administration and adverse reactions, read more.
The FDA approved a new therapy for the treatment plaque psoriasis among adult patients. For administration and adverse effects, read more.
Back to Top